Contributions
Abstract: P1124
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Cerebrospinal fluid (CSF) chitinasa 3-like 1 (CHI3L1) and light subunit of neurofilaments (NF-L) have consolidated their prognostic value in CIS patients to predict theconversion to multiple sclerosis (MS) and have also demonstrated a relation with the development of disability.
Other than physical disability, MS is associated with cognitive dysfunction. No biomarkers for cognitive impairment are available. In this study, we investigated the relation between CHI3L1 and NF-L with cognitive performance.
Methods: Sample collection and cognitive exploration were performed close in time (range: 0-6 month)at the moment of diagnostic. CSF CHI3L1 and NF-L levels were measured by enzyme-linked immunosorbent assay (ELISA).
The neuropsychological tests applied were: Brief Repeatable Battery: Selective Reminding Test (SRT), 10-36 Spatial Recall Test (10/36 SPART), Symbol Digit (SDMT), Paced Auditory Serial Addition Test (PASAT), Word List Generation (WLG). We added the Boston Naming Test (BNT), Trail Making Test (TMT), Letter-Number Sequencing (L&N), Hospital Anxiety Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS). Partial correlations were used to evaluate the association between CHI3L1, NF-L and cognitive performance.
Results: Fifty-one relapse-onset MS patients (mean age: 35.6 years; 76.5% females) were included in the study. A total of 94% of the patients were positive for IgG oligoclonal bands, and 35.3 % of them were also positive for lipid-specific IgM oligoclonal bands. Levels of education in the studied cohort were: 15.7% primary, 51.0% secondary and 33.3% tertiary. After adjusting for anxiety, CHI3L1 levels were positive correlated with worse outcomein TMT-A test (Spearman rho=0.377; p=0.007); while NF-L levels correlated with poor performance in WLG test (Spearman rho= -0.352; p= 0.012). TMT-A test assesses attention as well as information processing speed, which appears aggravated in patients with high levels of CHI3L1. However, WLG, an indicator of executive functions and verbal fluency, is altered when NF-L levels are elevated.
Conclusions: The results presented here suggest the capacity of CHI3L1 and NF-L to detect differences in cognitive performance at initial stages of the disease. Longitudinal studies will be required to assess the CHI3L1 and NF-L ability to predict long term cognitive impairment.
Disclosure:
Quintana E. reports no disclosures.
Gich J. reports no disclosures.
Coll C. reports no disclosures.
Salavedra J. reports no disclosures.
Muñoz-San Martín M. reports no disclosures.
Tomàs-Roig J. reports no disclosures.
Robles-Cedeño R. reports no disclosures
Matute C. report no disclosures.
Montalban X. has received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Phramaceuticals, Almirall and Roche.
Villar LM. has received compensation for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Genzyme, and Novartis.
Comabella M. has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Genzyme, and Novartis.
Perkal H. Reports no disclosures
Ramió-Torrentà Ll. has received compensation for consulting services and speaking honoraria from from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd and Almirall.
Abstract: P1124
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Cerebrospinal fluid (CSF) chitinasa 3-like 1 (CHI3L1) and light subunit of neurofilaments (NF-L) have consolidated their prognostic value in CIS patients to predict theconversion to multiple sclerosis (MS) and have also demonstrated a relation with the development of disability.
Other than physical disability, MS is associated with cognitive dysfunction. No biomarkers for cognitive impairment are available. In this study, we investigated the relation between CHI3L1 and NF-L with cognitive performance.
Methods: Sample collection and cognitive exploration were performed close in time (range: 0-6 month)at the moment of diagnostic. CSF CHI3L1 and NF-L levels were measured by enzyme-linked immunosorbent assay (ELISA).
The neuropsychological tests applied were: Brief Repeatable Battery: Selective Reminding Test (SRT), 10-36 Spatial Recall Test (10/36 SPART), Symbol Digit (SDMT), Paced Auditory Serial Addition Test (PASAT), Word List Generation (WLG). We added the Boston Naming Test (BNT), Trail Making Test (TMT), Letter-Number Sequencing (L&N), Hospital Anxiety Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS). Partial correlations were used to evaluate the association between CHI3L1, NF-L and cognitive performance.
Results: Fifty-one relapse-onset MS patients (mean age: 35.6 years; 76.5% females) were included in the study. A total of 94% of the patients were positive for IgG oligoclonal bands, and 35.3 % of them were also positive for lipid-specific IgM oligoclonal bands. Levels of education in the studied cohort were: 15.7% primary, 51.0% secondary and 33.3% tertiary. After adjusting for anxiety, CHI3L1 levels were positive correlated with worse outcomein TMT-A test (Spearman rho=0.377; p=0.007); while NF-L levels correlated with poor performance in WLG test (Spearman rho= -0.352; p= 0.012). TMT-A test assesses attention as well as information processing speed, which appears aggravated in patients with high levels of CHI3L1. However, WLG, an indicator of executive functions and verbal fluency, is altered when NF-L levels are elevated.
Conclusions: The results presented here suggest the capacity of CHI3L1 and NF-L to detect differences in cognitive performance at initial stages of the disease. Longitudinal studies will be required to assess the CHI3L1 and NF-L ability to predict long term cognitive impairment.
Disclosure:
Quintana E. reports no disclosures.
Gich J. reports no disclosures.
Coll C. reports no disclosures.
Salavedra J. reports no disclosures.
Muñoz-San Martín M. reports no disclosures.
Tomàs-Roig J. reports no disclosures.
Robles-Cedeño R. reports no disclosures
Matute C. report no disclosures.
Montalban X. has received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Phramaceuticals, Almirall and Roche.
Villar LM. has received compensation for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Genzyme, and Novartis.
Comabella M. has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Genzyme, and Novartis.
Perkal H. Reports no disclosures
Ramió-Torrentà Ll. has received compensation for consulting services and speaking honoraria from from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd and Almirall.